QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.